A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Launched by ELI LILLY AND COMPANY · Jun 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called retatrutide to see if it can help reduce long-lasting low back pain in people who are overweight or have obesity. The study will look at how well the medicine works and whether it is safe to use. Participants will be involved in the study for about 80 weeks, which is a little over a year and a half.

People who might be eligible to join are adults between 65 and 74 years old who have ongoing low back pain mainly in the lower back area, with or without pain spreading to the upper legs. They must have a body weight that classifies them as overweight or obese (a BMI of 27 or higher) and have tried at least once before to lose weight through diet without success. The study does not include people who have certain types of back pain, recent spine injections, significant recent weight changes, recent use of weight-loss drugs, prior or planned weight-loss surgery, or any form of diabetes. If you join, you can expect to be monitored closely over the study period to track your pain and any side effects from the medicine. This study is not yet open for enrollment but aims to find better treatments for people struggling with both weight issues and chronic low back pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have a history of axial-predominant low back pain
• • Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs
• • Have a body mass index (BMI) ≥27 kilograms per square meter (kg/m2) at screening
• • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
• Exclusion Criteria:
• • Have a non-axial origin low back pain
• • Have had botulinum or steroid injections to the spine within 1 year of screening
• • Have had trigger point injection to the spine within 6 months of screening
• • Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days prior to screening
• • Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening
• • Have a prior or planned surgical treatment for obesity
• • Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes